SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    du Bois A,Quinn M,Thigpen T, et al. 2004 Consensus statements on the management of ovarian cancer: final document of the third International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference, GCIG OCCC 2004. Ann Oncol. 2005; 16(suppl 8): viii7viii12.
  • 2
    Alberts DS,Liu PY,Hannigan EV,O'Toole R, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996; 335: 19501955.
  • 3
    Gadducci A,Carnino F,Chiara S, et al. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol Oncol. 2000; 76: 157162.
  • 4
    Markman M. Role of intraperitoneal chemotherapy in the front-line setting. J Clin Oncol. 2003; 21: 145s148s.
  • 5
    Armstrong D,Bundy B,Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006; 354: 3443.
  • 6
    Jaaback K,Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2006; 1: 128.
  • 7
    National Cancer Institute. Clinical announcement – intraperitoneal chemotherapy for ovarian cancer. Available at URL: http://ctep.cancer.gov/highlights/clin_annc_010506.pdf.
  • 8
    Markman M,Bundy BN,Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergoup study of the Gynecologic Oncology Group, Southwestern Oncology Group and Eastern Cooperative Oncology Group. J Clin Oncol. 2001; 19: 10011007.
  • 9
    Piccart MJ,Floquet A,Scarfone G, et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized Phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer. 2003; 13(suppl 2): 196203.
  • 10
    Wenzel L,Huang H,Armstrong D, et al. Quality of life (QOL) results of randomized trial of intravenous (IV) paclitaxel and cisplatin vs. IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group Study. [abstract]. Proc Am Soc Clin Oncol. 2004; 23: 454. Abstract 5026.
  • 11
    Markman M,Walker JL. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol. 2006; 24: 988994.
  • 12
    Walker JL,Armstrong DK,Huang HQ, et al. Intraperitoneal catheter outcomes in a Phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2006; 100: 2732.
  • 13
    Pujade-Lauraine E,Guastalla JP,Colombo N, et al. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol. 1996; 14: 343350.
  • 14
    Zeimet AG,Marth C. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol. 2003; 4: 415422.
  • 15
    Rustin GJS,Timmers P,Nelstrop A, et al. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol. 2006; 24: 4551.
  • 16
    Zeimet AG,Offner FA,Marth C, et al. Modulation of CA-125 release by inflammatory cytokines in human peritoneal mesothelial and ovarian cancer cells. Anticancer Res. 1997; 17: 31293132.